XTL Biopharmaceutica (Israel) Financial Diagnostics

XTLB -- Israel Stock  

ILS 9.10  0.10  1.11%

The small decline in market price for the last few months may raise some interest from investors as it closed today at a share price of 9.0 on 1.000 in trading volume. The company directors and management did not add much value to XTL Biopharmaceuticals Ltd investors in February. However, diversifying your holdings with XTL Biopharmaceuticals or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 3.6159. The above-average volatility is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from XTL Biopharmaceuticals Ltd partners. This diagnostics interface makes it easy to digest most current publicly released information about XTL Biopharmaceutica as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis XTL Biopharmaceutica price relationship with some important fundamental indicators such as market cap and management efficiency. See also Your Current Watchlist.

XTL Biopharmaceutica Note

The company had not issued any dividends in recent years. XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Raanana, Israel. XTL Biopharmaceutica is traded on Tel Aviv Stock Exchange in Israel. For more information please call the company at 972 9 955 7080 or visit http://www.xtlbio.com.

XTL Biopharmaceuticals Alerts

XTL Biopharmaceutica is not yet fully synchronised with the market data
XTL Biopharmaceutica generates negative expected return over the last 30 days
XTL Biopharmaceutica has high historical volatility and very poor performance
XTL Biopharmaceutica has high likelihood to experience some financial distress in the next 2 years
XTL BIOPHARMAC has accumulated about 5.41M in cash with (1.12M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.

Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 45.25M.

Management Efficiency

XTL Biopharmaceuticals has return on total asset (ROA) of (7.5) % which means that it has lost $7.5 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 35.57 % meaning that it generated $35.57 on every $100 dollars invested by stockholders.

XTL Biopharmaceutica Technical and Predictive Indicators

Did you try this?

Run Price Exposure Probability Now


Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Price Exposure Probability

Also Currentnly Active

Purchased over 500 shares of
a day ago
Traded for 152.16
Purchased over 10K shares of
a day ago
Traded for 0.57
Purchased over 100 shares of
a day ago
Traded for 29.43
See also Your Current Watchlist. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Search macroaxis.com